• Bazedoxifene: Selective Estrogen Receptor Modulator in Osteo

  2026-08-03

  Bazedoxifene stands out as a third-generation selective estrogen receptor modulator (SERM) optimized for postmenopausal osteoporosis models. Its tissue-selective activity and robust inhibition of estrogen-driven pathways make it indispensable for both bone biology and translational endocrine studies.

• Pexmetinib (ARRY-614): Optimizing Inflammatory Cytokine Assa

  2026-08-03

  Pexmetinib (ARRY-614) uniquely combines dual kinase inhibition with conformational modulation for precise inflammatory cytokine suppression. This guide details workflow enhancements, troubleshooting, and new mechanistic insights that help researchers unlock reproducibility and specificity in signaling assays.

• Redefining In Vitro Drug Response Metrics in Cancer Research

  2026-08-02

  Schwartz's dissertation introduces a rigorous framework for distinguishing between proliferative arrest and cell death in evaluating anti-cancer agents in vitro. By clarifying metric selection and interpretation, this work advances mechanistic insight and improves the predictive value of preclinical drug screening.

• BKT140 (BL-8040): Applied CXCR4 Antagonism for Oncology Rese

  2026-08-01

  BKT140 (BL-8040) enables robust CXCR4-mediated chemotaxis inhibition and apoptosis induction in tumor and stem cell workflows, with unmatched solubility and translational flexibility. This guide details actionable protocols, troubleshooting insights, and comparative strengths for applied oncology and hematopoietic research.

• MLN2238: Precision Proteasome β5 Subunit Inhibitor Workflows

  2026-07-31

  MLN2238 empowers researchers to dissect proteasome β5 subunit inhibition with nanomolar precision, supporting advanced oncology and proteostasis applications—even in drug-resistant models. This guide translates bench-validated workflows, troubleshooting, and novel CRTC-CREB axis insights into actionable steps for robust experimental design.

• NU7441 (KU-57788): Precision DNA-PK Inhibition in Oncology R

  2026-07-31

  NU7441 (KU-57788) empowers advanced DNA repair and oncology research by enabling highly selective, nanomolar inhibition of DNA-PK. This guide demystifies experimental workflows, troubleshooting strategies, and comparative advantages, positioning NU7441 as a cornerstone for robust cell cycle and DNA damage response studies.

• Digoxin: Na+/K+ ATPase Pump Inhibitor for Cardiac & Antivira

  2026-07-30

  Digoxin is a high-purity Na+/K+ ATPase pump inhibitor with proven efficacy in modulating cardiac contractility and inhibiting chikungunya virus infection in specific human cell models. Supplied by APExBIO, Digoxin (SKU B7684) offers robust documentation for translational applications. Its cell-type specificity and solubility profile define both its utility and experimental boundaries.

• Differential SHH Pathway Expression in Penile Development: G

  2026-07-30

  This study uncovers how distinct timing and levels of Sonic Hedgehog (SHH), Fgf10, and Fgfr2 expression drive differences in prepuce and urethral groove formation between guinea pigs and mice. The findings highlight key mechanistic distinctions with direct implications for the modeling of human congenital urogenital malformations and developmental biology research.

• Carfilzomib (PR-171) Protocols: Applied Proteasome Inhibitio

  2026-07-29

  Carfilzomib (PR-171) is redefining proteasome inhibition in cancer research, enabling robust apoptosis induction and workflow flexibility. This article provides evidence-driven protocols, advanced troubleshooting, and unique insights for maximizing experimental impact with APExBIO’s industry-trusted Carfilzomib.

• BCKAs Induce Normoxic HIF1α Activation in Vascular Cells

  2026-07-29

  This study uncovers that branched chain α-ketoacids (BCKAs) can activate HIF1α signaling in vascular cells under normal oxygen conditions, revealing a novel metabolic pathway with relevance to pulmonary vascular pathology. The findings redefine how intrinsic metabolites regulate vascular cell function and suggest new avenues for modeling disease-relevant phenotypes in vitro.

• Solving Lab Challenges with PYR-41, Inhibitor of Ubiquitin-A

  2026-07-28

  This article provides a scenario-driven, evidence-based guide for deploying PYR-41, inhibitor of Ubiquitin-Activating Enzyme (E1) (SKU B1492), in cell viability, immunology, and inflammation assays. By addressing real-world laboratory pitfalls and referencing recent mechanistic studies, we highlight how PYR-41 enables reliable interrogation of the ubiquitin-proteasome system and NF-κB signaling, supporting reproducible, high-impact biomedical research.

• DGLA-Induced Ferroptosis in AML via ACSL4-Mediated Lipid Rep

  2026-07-28

  This study uncovers how exogenous dihomo-γ-linolenic acid (DGLA) triggers ferroptosis in acute myeloid leukemia (AML) cells by reprogramming lipid metabolism through ACSL4. These findings highlight a metabolic vulnerability in AML and suggest novel therapeutic strategies targeting ferroptosis.

• Dissecting Drug Responses: Enhanced In Vitro Cancer Assays

  2026-07-27

  Schwartz’s dissertation advances in vitro evaluation of anticancer drugs by distinguishing between proliferative arrest and cell death using refined viability metrics. These methodological insights enable more precise assessment of agents like topoisomerase 1 inhibitors, with important implications for translational oncology and preclinical drug development.

• Topotecan HCl: DNA Damage, Selectivity, and Precision in Onc

  2026-07-27

  Explore how Topotecan HCl, a leading topoisomerase 1 inhibitor, enables precise control of DNA damage and apoptosis in cancer models. This article uniquely bridges mechanistic insights with selectivity principles to empower advanced oncology research.

• IBDV VP3 Drives IRF7 Degradation via Proteasome for Immune E

  2026-07-26

  This study uncovers how infectious bursal disease virus (IBDV) leverages its VP3 protein to degrade interferon regulatory factor 7 (IRF7) through proteasome-mediated pathways, suppressing host antiviral defenses and enhancing viral replication in chicken cells. These findings reveal a mechanistic link between viral protein function and the host ubiquitin-proteasome system, opening new research avenues in viral immune evasion and antiviral strategy development.

16938 records 1/1130 page Next 12345 下5页 Last page